ACRP blog
FEBRUARY 11, 2025
If theres one thing clinical researchers can count on when it comes to regulations and guidance from governing bodies, its change. The Academy agenda covers: Human research protections U.S. Learn more about HCCA The post Keeping Up with the Clinical Research Compliance Landscape appeared first on ACRP.
Pharmaceutical Technology
FEBRUARY 24, 2023
The European Federation of Pharmaceutical Industries and Associations (EFPIA), the trade organisation for branded drugs, said the proposals ‘would irretrievably sabotage’ the EU pharma industry and ‘would send Europe to the back of the queue for healthcare treatments, clinical research, jobs, and global investment’ The draft’s (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
MAY 1, 2024
Her background also includes significant roles such as serving as an adjunct professor at the George Washington University Law School, where she coaches health law moot court teams, and engaging actively with key industry groups like the Society for Clinical Research Associates and the Food and Drug Law Institute.
The Pharma Data
JANUARY 4, 2021
Burr Boulevard, Teaneck, NJ 07666 (3) President: Yasushi Miyazawa (4) Scope of business: Clinical research and development (5) Paid in capital: US$100,000. Outline of the new company (1) Company name: Meiji Pharma USA Inc. (2) Location: 500 Frank W. Integrated Reports: [link].
pharmaphorum
JUNE 8, 2021
While all of the top ten best-selling oncology drugs in the US in 2019 were innovative therapies, four out of the top ten best-selling oncology drugs in China were for conventional chemotherapy. “In In addition, the pharmaceutical industry in China is still heavily dependent on generic drugs.”. About the interviewee.
Cloudbyz
MARCH 5, 2024
The choice between developing a biologic or a small molecule drug often depends on the nature of the disease target, the desired mechanism of action, and the feasibility of manufacturing and delivery. Monitoring and managing immunogenicity is a complex aspect of clinical trials for biologics.
FDA Law Blog
APRIL 8, 2024
For generic drug manufacturing facilities specifically, the numbers are 63% and 87%. We recently summarized another GAO report which described challenges FDA continues to face with clinical research inspections.
Expert insights. Personalized for you.
59 
Let's personalize your content